NasdaqGS - Nasdaq Real Time Price • USD
Gilead Sciences, Inc. (GILD)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:55 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
27,116,000.00
27,116,000.00
27,281,000.00
27,305,000.00
24,689,000.00
Cost of Revenue
6,498,000.00
6,498,000.00
5,657,000.00
6,601,000.00
4,572,000.00
Gross Profit
20,618,000.00
20,618,000.00
21,624,000.00
20,704,000.00
20,117,000.00
Operating Expense
11,808,000.00
11,808,000.00
10,650,000.00
9,847,000.00
10,190,000.00
Operating Income
8,810,000.00
8,810,000.00
10,974,000.00
10,857,000.00
9,927,000.00
Net Non Operating Interest Income Expense
-944,000.00
-944,000.00
-935,000.00
-1,001,000.00
-984,000.00
Other Income Expense
-1,007,000.00
-1,007,000.00
-4,225,000.00
-1,578,000.00
-7,274,000.00
Pretax Income
6,859,000.00
6,859,000.00
5,814,000.00
8,278,000.00
1,669,000.00
Tax Provision
1,247,000.00
1,247,000.00
1,248,000.00
2,077,000.00
1,580,000.00
Net Income Common Stockholders
5,665,000.00
5,665,000.00
4,592,000.00
6,225,000.00
123,000.00
Diluted NI Available to Com Stockholders
5,665,000.00
5,665,000.00
4,592,000.00
6,225,000.00
123,000.00
Basic EPS
4.54
4.54
3.66
4.96
0.10
Diluted EPS
4.50
4.50
3.64
4.93
0.10
Basic Average Shares
1,248,000.00
1,248,000.00
1,255,000.00
1,256,000.00
1,257,000.00
Diluted Average Shares
1,258,000.00
1,258,000.00
1,262,000.00
1,262,000.00
1,263,000.00
Total Operating Income as Reported
7,605,000.00
7,605,000.00
7,330,000.00
9,918,000.00
4,071,000.00
Total Expenses
18,306,000.00
18,306,000.00
16,307,000.00
16,448,000.00
14,762,000.00
Net Income from Continuing & Discontinued Operation
5,665,000.00
5,665,000.00
4,592,000.00
6,225,000.00
123,000.00
Normalized Income
6,650,690.00
6,650,690.00
7,452,540.00
6,928,311.00
4,397,880.00
Interest Expense
944,000.00
944,000.00
935,000.00
1,001,000.00
984,000.00
Net Interest Income
-944,000.00
-944,000.00
-935,000.00
-1,001,000.00
-984,000.00
EBIT
7,803,000.00
7,803,000.00
6,749,000.00
9,279,000.00
2,653,000.00
EBITDA
10,496,000.00
10,496,000.00
8,852,000.00
11,329,000.00
4,133,000.00
Reconciled Cost of Revenue
6,498,000.00
6,498,000.00
5,657,000.00
6,601,000.00
4,572,000.00
Reconciled Depreciation
2,693,000.00
2,693,000.00
2,103,000.00
2,050,000.00
1,480,000.00
Net Income from Continuing Operation Net Minority Interest
5,665,000.00
5,665,000.00
4,592,000.00
6,225,000.00
123,000.00
Total Unusual Items Excluding Goodwill
-1,205,000.00
-1,205,000.00
-3,644,000.00
-939,000.00
-5,856,000.00
Total Unusual Items
-1,205,000.00
-1,205,000.00
-3,644,000.00
-939,000.00
-5,856,000.00
Normalized EBITDA
11,701,000.00
11,701,000.00
12,496,000.00
12,268,000.00
9,989,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-219,310.00
-219,310.00
-783,460.00
-235,689.00
-1,581,120.00
12/31/2020 - 1/22/1992
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BMY Bristol-Myers Squibb Company
44.85
+0.34%
BIIB Biogen Inc.
208.90
+3.18%
ABBV AbbVie Inc.
159.62
-4.58%
MRK Merck & Co., Inc.
131.20
+0.37%
PFE Pfizer Inc.
25.40
+0.55%
AZN AstraZeneca PLC
75.17
+0.19%
AMGN Amgen Inc.
269.98
+0.22%
JNJ Johnson & Johnson
146.14
-0.46%
SNY Sanofi
49.13
-0.47%
LLY Eli Lilly and Company
733.51
+1.19%